Business Wire

Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design

17.6.2025 07:01:00 EEST | Business Wire | Press release

Share

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of the square version of the Amazfit Active 2, a new addition to its fitness smartwatch line that offers the same powerful features and premium experience as the recently launched round Active 2 — now in a modern, square form factor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250616213563/en/

Amazfit Active 2 Square

Same Features. New Shape.

Debuting at CES 2025 and featured at Pepcom and ShowStoppers, the Active 2 Square is designed for consumers who prefer a bold, geometric aesthetic without compromising performance, durability, or advanced health and fitness tracking.

Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame, the Amazfit Active 2 delivers an optimal visual experience with a peak brightness of 2,000 nits, ensuring clarity even in bright light.

The graceful metal finish adds a sophisticated touch, perfectly complementing modern, style-conscious lifestyles. Its distinctive geometric form reflects a unique design identity and its intuitive interface and expansive viewing surface provide seamless access to health metrics, messages, and workouts. The device retains the full suite of features that made the round Active 2 a standout.

Product Specs

  • Latest Generation Biosensor: The BioTracker™ 6.0 PPG biosensor features a dual-LED and 5PD build, which picks up more biometric signals for enhanced precision in health monitoring and measurement.
  • Upgraded Heart Rate and Sleep Algorithms: The PulsePrecision™ algorithm enhances heart rate tracking accuracy to the level of the Amazfit T-Rex 3, while the RestoreIQ™ algorithm gives sleep monitoring a similar accuracy boost.
  • Additional Sensors: Compared to the previous generation of Amazfit Active, the new release adds a barometer for accurate altitude measurements and support of new sports like skiing, along with an accelerometer and gyroscope for precise recognition of sleep and movement, and an ambient light sensor for optimal display under varying light conditions.
  • Extended Battery Life: With a robust 10-day battery life under typical use, the Active 2 Square is a device that won't need recharging every night.
  • Zepp Flow™: Enables users to control their watch settings, adjust their calendar, and more with just their voice, while also granting Android users the ability to reply to instant messages with either keyboard or speech-to-text input.

Fitness and Wellness Features

  • Dynamic Fitness Modes: Over 160 sports modes including official HYROX Race Mode, a smart Strength Training mode that can auto-detect specific exercises and intelligently count reps, sets, and rest time, and new winter sports like Skiing.
  • Offline Maps with Turn Directions: Supported by 5 satellite systems, users can navigate with ease by importing offline maps and route files to the watch that come with turn-by-turn directions, which can be followed on-screen or broadcast via the built-in speaker or the user's connected Bluetooth headphones.
  • Zepp Coach™ Integration: Offers personalized training and running plans, empowering users of all levels to achieve fitness milestones from 3K runs to full marathons.
  • Tailored for Women: With the Wild.AI mini app, women can connect to their accounts directly from the watch for personalized wellness insights tied to their menstrual and hormonal cycles.
  • Advanced Health Insights: A daily Readiness score summarizes mental and physical recovery and provides actionable insights, while the HRV feature delivers specialized recovery data.

Availability and Pricing

The Amazfit Active 2 Square is available for purchase beginning today on Amazfit.com and Amazon.Priced at $149.99 USD or €149.90 euro, the Active 2 Square delivers premium features and performance at an unbeatable value.

For more information, please visit https://www.amazfit.com/en/ and follow us on Facebook, Instagram, X (formerly Twitter) and YouTube.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.

Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, “Discover Amazing,” encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health’s proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals.

Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit www.amazfit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250616213563/en/

Contacts

Media Contact
Mary Thompson Woodbury
Head of PR, North America
mary.woodbury@zepp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye